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Immune checkpoint inhibitors (ICIs) and kinase inhibi-
tors (BRAF and MEK inhibitors) have improved clinical 
outcomes in patients with advanced BRAFV600 mutant 
melanoma. Preliminary results from ongoing, phase III 
clinical trials of combined ICIs and kinase inhibitors have 
shown a manageable safety profile with promising efficacy. 
However, unbridled activation of the immune system may 
be associated with a wide spectrum of autoimmune or 
inflammatory side-effects. We describe here a case of a 
62-year-old woman with stage IIID melanoma, treated with 
anti-PD1, BRAF and MEK inhibitors, which resulted in 
proximal hair depigmentation of the scalp and patchy hair 
loss, with complete response (CR) of the disease. It can be 
hypothesized, that this case represents a clinical example 
of cross T-cell reactivity against shared antigens between 
tumour cells and melanocytes on previously protected sites 
on the hair follicle, which may indicate an anti-tumour 
efficacy in patients treated with ICI-based therapy.
CASE REPORT
ICIs have shown a remarkable response and survival benefit in 
metastatic melanoma (1). Their enhanced anti-tumour activity 
accrues through the inhibition of negative regulators of immune 
activation, such as CTLA-4 or PD-1, which, on the other hand, 
can deregulate immunological homeostasis, resulting in immune-
related adverse events (irAE) (2). Alopecia areata (AA), an 
autoimmune disorder of patchy hair loss, has been reported in 
0.9% of patients being treated with pembrolizumab (anti-PD1 
monoclonal antibody (mAb)) and in 2% of patients being treated 
with nivolumab (anti-PD1 mAb) alone (3). We describe here a case 
of a 62-year-old woman with unresectable, stage IIID (AJCCv8), 
BRAFV600E mutant metastatic melanoma treated with anti-PD1 
(spartalizumab 400 mg Q4W), BRAF inhibitor (dabrafenib 150 mg 
BID) and MEK inhibitor (trametinib 2 mg QD) in a clinical trial 
(NCT02967692). She was diagnosed with a polypoid cutaneous 
melanoma on her left lower leg (Breslow thickness 4.3 mm, with 
ulceration, without regression, pT4b) and presented with multiple 
iliac and inguinal lymph node metastases on the left side, as well 
as in-transit metastases on her left leg, with no distant metastases 
(N3c, M0). Her personal and family medical history was insig-
nificant for any autoimmune or skin and hair diseases. She was 
treated initially with spartalizumab + dabrafenib + trametinib for 
3 treatment cycles and developed immune-related (ir) Sjögren 
syndrome (Grade 2, CTCAEv4), secondary to her melanoma 
treatment with clinical signs of xerostomia and xerophthalmia, 
laboratory signs of elevated antinuclear antibodies (ANA 1:320) 
and anti-SSA antibodies > 240 U/ml (n < 10), and histological signs 
of chronic granulomatous sialadenitis in a lower lip biopsy. She 
had received 7 treatment cycles, resulting in a complete response 
(CR) of her tumour. 
Six months after the initiation of treatment the patient presented 
with well-demarcated areas of proximal hair depigmentation, 
which resulted in patchy hair loss limited to her scalp, and sym-
metrical patches of depigmentation on the skin of both forearms, 
consistent with “vitiligo-like” depigmentation. No nail or muco-
sal alterations were observed. Clinical examination of the scalp 
revealed diffuse hair thinning and well-defined areas of proximal 
depigmentation of the hair, resulting in non-scarring alopecia (Fig. 
1a). The hair pull test was positive. Dermoscopy showed multiple 
yellow dots surrounding the hair follicle openings, vellus hair and 
broken hair (Fig. 1b). Histopathology of the scalp revealed mild 
perifollicular lymphocytic inflammation, intrafollicular infiltrate 
of CD8+ T cells mostly in the deep dermis, and isolated CD4+ T 
cells (Fig. 1c). Laboratory investigations were unremarkable for 
thyroid dysfunction or an underlying infection. A diagnosis of 
immune-related AA (irAA) was established. She began treatment 
with topical steroids (clobetasol foam), resulting in an ameliora-
tion of the alopecia. In areas of previous hair loss she developed 
regrowth of white hair.
DISCUSSION
AA is an autoimmune condition affecting the hair follicle, 
and is characterized histologically by immune infiltration 
against pigmented hair, with perifollicular lymphocytic in-
filtrates, primarily CD4+ (4). There have been rare reports 
of AA secondary to ICIs (3). Due to the rare incidence 
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Fig. 1. (a) Scalp with patchy hair loss with multiple, well-defined areas of non-scarring alopecia, diffuse hair thinning and proximal depigmentation. 
(b) Dermoscopy with multiple yellow dots surrounding the hair follicle openings, short velous hair and broken hair. Scale bar corresponds to 1 mm. (c) 
Immunohistochemical staining for CD8+ of a biopsy specimen (original magnification ×100) with mild perifollicular lymphocytic inflammation, intrafollicular 
infiltrate of CD8+ T cells mostly in the deep dermis and isolated CD4+ T cells.
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of this irAE, very little data concerning its clinical and 
histological presentation are available. It is notable that 
vitiligo-like depigmentation is correlated with anti-tumour 
efficacy in patients with metastatic melanoma, treated with 
immunotherapy (5). In contrast to the observed poliosis 
associated with hair regrowth in areas of previous hair 
loss in AA (6), in the above-mentioned case, proximal hair 
depigmentation of well-demarcated areas on the scalp was 
observed prior to hair loss, which subsequently resulted in 
alopecia. We hypothesize that this case of localized hair-
depigmentation, also similarly described in vitiligo-like 
depigmentation cases (5), is an example of an antigen-
specific immunity in patients with melanoma. Hair loss 
is the subsequent result of this “off-target” attack. As a 
possible pathomechanism we consider a T-lymphocyte-
mediated cross-reactivity between tumour cell antigens 
and related antigens in the protected melanocytes of the 
hair bulb, as described in ir-AA (2). This theory correlates 
with our immunohistochemical findings, of intrafollicular 
predominant CD8+ infiltrates (Fig. 1c). Previously repor-
ted cases of localized hair re-pigmentation in melanoma 
have correlated melanin production from melanoma cells 
in hair follicle melanocytes by paracrine stimulation, 
probably induced by growth factors, such as c-kit ligand 
(7). It is notable that, in both cases, no melanoma cells 
were seen histologically in the hair papillae.
It has been proposed that microphthalmia-associated 
transcription factor (MITF), may contribute to the connec-
tion between melanoma response to immuno therapy and 
vitiligo (8). Malignant transformation of the melanocytes 
occurs, among other mechanisms, also as a result of the 
disruption of the regular function of MITF as a melanocyte 
lineage promoter, thus prompting the immune system to 
recognize specific epitopes not only on melanoma cells, 
but also on normal melanocytes. These findings may 
correlate with the clinical observation of pigmented hair 
being lost preferentially to non-pigmented hair and also 
with the observation that in most cases hair regrowth tends 
to appear nonpigmented. In vivo data suggest that optimal 
transfer of hair loss in mice requires both CD4+ and CD8+ 
T cells (9). In addition to T cells, increased IFN-γ response 
indicative of T-cell activation following enhanced anti-
tumour activity induced by ICI may also be involved in 
the pathophysiology of the disease. Besides, clinical and 
preclinical data prove that blockade of common signalling 
pathways downstream of cytokine receptors (JAK/STAT) 
could clinically reverse AA (10).
Recently, ongoing clinical trials combining immuno-
therapy and targeted therapy for the treatment of metastatic 
melanoma have shown promising efficacy with a mana-
geable safety profile (11). Dual MAPK pathway inhibition 
through BRAF and MEK inhibitors induce significant 
changes in the tumour microenvironment, thus making 
tumours more susceptible to immunotherapy (12). Howe-
ver, the release of numerous pro-inflammatory cytokines 
and kinase inhibitors may lead to aberrant immune acti-
vation (13). It can be hypothesized that this dual immune 
activation may be associated with susceptibility to irAA 
in predisposed individuals. However, further research is 
needed to determine whether the frequency of these events 
is increased compared with immunotherapy alone.
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